Clinical trials: Liver Biopsy
NASH - Nonalcoholic Steatohepatitis
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at Randomization and every four weeks from Week 4 through Week 52 and through End of Study period.
- Trial name
- VOYAGE (NCT04173065)
- Testing
- VK2809
- Where
- 79 sites in United States, Belgium and 3 more
- Volunteers
- 248 people
- Sponsor
- Viking Therapeutics, Inc.
Pancreas Disease, Liver Diseases
Motorized Fine Needle Biopsy vs Standard Needles
Recent improvements in punctures techniques and needles now allow for the collection of high-quality specimens comparable to core needle biopsy.
- Trial name
- NCT06298604
- Testing
- EUS-guided standard fine needle biopsy, EUS-guided motorized fine needle biopsy
- Where
- Ecuador
- Volunteers
- 60 people
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
HEPATITIS B CHRONIC, Hepatitis B Chronic Infection
Bepirovirsen Liver Biopsy Study
Bepirovirsen Liver Biopsy study is a single centre open label phase II study to examine the antiviral and immunological effects of bepirovirsen in CHB patients both treated and untreated with HBsAg<1000 IU/ml
- Trial name
- GSK Biopsy (NCT07696520)
- Testing
- Bepirovirsen, Liver biopsy, Optional Liver biopsy
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Health System, Singapore
Liver Cirrhosis
EUS-guided Versus Percutaneous Ultrasound-guided Biopsy for Parenchymal Liver Disease
Liver biopsy may be indicated in various clinical scenarios to help diagnose and manage liver diseases. Endoscopic ultrasound (EUS) liver biopsy and percutaneous USG guided liver biopsy are two methods used to obtain liver tissue…
- Trial name
- NCT06047327
- Testing
- EUS guided liver biopsy, Percutaneous Liver Biopsy
- Where
- India
- Volunteers
- 90 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepato Cellular Carcinoma (HCC)
Hepatocellular Carcinoma Identification Using Delta-HLD
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting…
- Trial name
- HIDE (NCT07148310)
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- Epiliquid Holding, Inc
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.
The primary objective of this study is to assess the clinical performance of LIVERFAStTM In Vitro Diagnostic (IVD) Tests (Fibrosis score, Activity score and Steatosis score) in NAFLD suspected patients for staging of fibrosis and…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
- Trial name
- NCT04579874
- Testing
- LIVERFASt
- Where
- 8 sites in United States
- Volunteers
- 241 people
- Sponsor
- Fibronostics USA, Inc
Liver Fibrosis, Liver Diseases
Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave Elastography
Chronic liver disease is a major problem in the general population and there is an unmet need to diagnose(and screen) for liver disease with using noninvasive, cost-effective and sensitive techniques.The investigators hypothesize…
- Trial name
- NCT03342560
- Testing
- Sonographic SWE measurements with 4 different ultrasound systems
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Cancer Abdomen
Epione® Post-Market Clinical Follow-up Study
Post-Market Clinical Follow-up study in order to consolidate performance and safety data of the EPIONE® device when used for percutaneous procedures in the abdomen
- Trial name
- SaFE (NCT05529979)
- Testing
- EPIONE® CT-Guided Percutaneous procedures
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Quantum Surgical
Hepatitis C
History of Hepatitis C in Volunteer Blood Donors
Hepatitis C is a disease of the liver caused by the Hepatitis C Virus (HCV). Patients with hepatitis C may feel well and show no signs or symptoms of being ill.
- Trial name
- NCT00001982
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Biopsy
Endoscopic Ultrasound vs Percutaneous Route for Liver Biopsy
This study is to evaluate and directly compare the technical success, tissue quality, diagnostic efficacy and safety profile of Percutaneous and Endoscopic Ultrasound-guided Liver Biopsy.
- Trial name
- NCT04003766
- Testing
- biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- AdventHealth
NASH - Nonalcoholic Steatohepatitis
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
- Trial name
- ENLIVEN (NCT04929483)
- Testing
- BIO89-100
- Where
- 89 sites in United States, Puerto Rico
- Volunteers
- 222 people
- Sponsor
- 89bio, Inc.
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor).
- Trial name
- MIRNA (NCT04321031)
- Testing
- PF-06865571, PF-05221304
- Where
- 291 sites in United States, Bulgaria and 10 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.
Liquid biopsy technology based on high-throughput sequencing can detect trace signals in the early stage of cancer in plasma free DNA, so it has become a new technology suitable for tumor diagnosis and screening.Relying on the…
- Trial name
- NCT06134973
- Testing
- ultrasonic testing
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Tianjin Third Central Hospital
NAFLD
Hydroxytyrosol and Vitamin E in Pediatric NASH
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children.
- Trial name
- NCT02842567
- Testing
- Hydroxytyrosol plus Vitamin E
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Percutaneous Liver Biopsy
Percutaneos Liver Biopsy in Pediatric Patient : Diagnostic Significance and Pattern of Liver Diseases
In this study, we aim to evaluate the spectrum and pattern of liver diseases diagnosed by percutaneous tru-cut needle liver biopsy.
- Trial name
- NCT06773390
- Testing
- Percutaneous liver biposy
- Volunteers
- 40 people
- Sponsor
- Assiut University
Colorectal Cancer, Colorectal Neoplasms
Early Detection of Advanced Adenomas and Colorectal Cancer
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma
- Trial name
- AACRC (NCT06342440)
- Testing
- DENEB
- Where
- 6 sites in United States, China and 3 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Hepatitis B, Chronic
Tenofovir Alafenamide With Fine Needle Aspiration Biopsy in Chronic Hepatitis B:
The objective of this study is to identify immunological mechanisms that contribute to normalization of liver inflammation in chronic hepatitis B (CHB) patients starting the antiviral nucleoside analogue, Tenofovir alafenamide…
- Trial name
- NCT04070079
- Testing
- Tenofovir Alafenamide
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated…
- Trial name
- NCT06920043
- Testing
- Efimosfermin
- Where
- 30 sites in United States
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
HCC, Cirrhosis, Liver
The Utility of Breath Biopsy as a Screening Tool for HCC
The aim of this pilot study is to examine whether there is a discriminating ability of the breath sample analysis to capture biomarkers specific to the HCC in the breath of affected individuals.
- Trial name
- BrtH-C (NCT04326491)
- Testing
- Breath Biopsy
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Aberdeen
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy on TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04906421
- Testing
- TVB-2640
- Where
- 117 sites in United States, Canada and 2 more
- Volunteers
- 168 people
- Sponsor
- Sagimet Biosciences Inc.